Portage Biotech - PRTG Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.33
  • Forecasted Upside: 228.80 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.88
▼ -0.08 (-1.34%)

This chart shows the closing price for PRTG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Portage Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTG

Analyst Price Target is $19.33
▲ +228.80% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Portage Biotech in the last 3 months. The average price target is $19.33, with a high forecast of $22.00 and a low forecast of $18.00. The average price target represents a 228.80% upside from the last price of $5.88.

This chart shows the closing price for PRTG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Portage Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2022Cantor FitzgeraldLower Target$26.00 ➝ $18.00Low
11/30/2022OppenheimerLower TargetOutperform$26.00 ➝ $18.00Low
9/21/2022Cantor FitzgeraldReiterated RatingOverweightLow
9/20/2022HC WainwrightLower TargetBuy$32.00 ➝ $22.00Low
7/15/2022OppenheimerInitiated CoverageBuy$26.00Low
3/7/2022HC WainwrightInitiated CoverageBuy$32.00Medium
9/20/2021OppenheimerInitiated CoverageOutperform$30.00High
9/2/2021B. RileyInitiated CoverageBuy$40.00Low
8/19/2021Cantor FitzgeraldInitiated CoverageOverweight$35.00Low
(Data available from 12/1/2017 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/4/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/4/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/3/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/2/2022
  • 3 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/1/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/1/2022

Current Sentiment

  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Portage Biotech logo
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and NT230-6 that is in Phase I/II clinical trials for the treatment of tumors. It also provides Nanolipogel (NLG) co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.
Read More

Today's Range

Now: $5.88
Low: $5.60
High: $5.96

50 Day Range

MA: $6.45
Low: $5.50
High: $7.53

52 Week Range

Now: $5.88
Low: $4.62
High: $16.68

Volume

5,305 shs

Average Volume

26,417 shs

Market Capitalization

$99.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.48

Frequently Asked Questions

What sell-side analysts currently cover shares of Portage Biotech?

The following Wall Street research analysts have issued stock ratings on Portage Biotech in the last year: Cantor Fitzgerald, HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for PRTG.

What is the current price target for Portage Biotech?

3 Wall Street analysts have set twelve-month price targets for Portage Biotech in the last year. Their average twelve-month price target is $19.33, suggesting a possible upside of 228.8%. HC Wainwright has the highest price target set, predicting PRTG will reach $22.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $18.00 for Portage Biotech in the next year.
View the latest price targets for PRTG.

What is the current consensus analyst rating for Portage Biotech?

Portage Biotech currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTG will outperform the market and that investors should add to their positions of Portage Biotech.
View the latest ratings for PRTG.

What other companies compete with Portage Biotech?

Other companies that are similar to Portage Biotech include Profound Medical, HEXO, Cellectis, XBiotech and Mereo BioPharma Group. Learn More about companies similar to Portage Biotech.

How do I contact Portage Biotech's investor relations team?

Portage Biotech's physical mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The company's listed phone number is 416-929-1806. The official website for Portage Biotech is www.portagebiotech.com. Learn More about contacing Portage Biotech investor relations.